India Pharma 2026 Conference
Analysis based on 6 articles · First reported Apr 12, 2026 · Last updated Apr 14, 2026
The event signals a strategic shift in India's pharmaceutical sector towards high-value segments like biologics and biosimilars, supported by significant government investment and policy initiatives. This focus on innovation and self-reliance is expected to boost the growth prospects of pharmaceutical companies operating in India and attract global partnerships, potentially leading to increased R&D spending and new product development.
The 9th edition of India Pharma 2026, a two-day conference organized by the India — Ministry of Chemicals and Fertilizers, Ministry of Chemicals & Fertilizers, Government of India, in collaboration with the Federation of Indian Chambers of Commerce & Industry and the Indian Pharmaceutical Alliance, commenced in New Delhi. Union Minister Jagad Prakash Nadda and Minister of State Haripriya Patel highlighted India's transition from a global generics leader to an emerging biopharma innovation hub. Key initiatives such as the Biopharma Shakti Initiative (₹10,000 crore outlay) and PRIP scheme were emphasized to foster research and development. The conference focuses on innovation, self-reliance, and global leadership, with discussions on AI in drug discovery, next-generation technologies, and strengthening regulatory ecosystems. Industry leaders from Mankind Pharma and Cipla also participated, underscoring the importance of collaboration and robust manufacturing capabilities.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard